Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M |
| Total Depreciation and Amortization | 304.00K | 294.00K | 322.00K | 325.00K | 366.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 867.00K |
| Total Other Non-Cash Items | 2.77M | 9.50M | 3.38M | 3.64M | -60.24M |
| Change in Net Operating Assets | -2.60M | -5.88M | -4.28M | 298.00K | -4.85M |
| Cash from Operations | -18.31M | -21.62M | -21.50M | -19.80M | -16.12M |
| Capital Expenditure | 2.00K | -35.00K | -201.00K | -140.00K | -17.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.00K | -- | -- | -- | 7.00K |
| Cash from Investing | 13.00K | -35.00K | -201.00K | -140.00K | -10.00K |
| Total Debt Issued | -- | -- | -- | -- | 39.55M |
| Total Debt Repaid | -- | -- | -- | -- | -43.00M |
| Issuance of Common Stock | -- | 6.72M | 70.48M | 26.00K | -- |
| Repurchase of Common Stock | -360.00K | -- | -- | -- | -423.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.00K | -127.00K | -13.00K | -48.00K | -375.00K |
| Cash from Financing | -357.00K | 6.60M | 70.47M | -22.00K | -4.25M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.65M | -15.06M | 48.76M | -19.96M | -20.38M |